Skip to main content
. 2018 Apr 19;3(8):e99263. doi: 10.1172/jci.insight.99263

Figure 4. Validation of GMP-grade iExosome efficacy in vitro.

Figure 4

(A) Representative dot plot and (B) quantification of flow cytometry analysis of apoptosis in Panc-1 cells induced by MSC Ctrl Exo, MSC siScrbl iExo, MSC siKrasG12D–1 iExo, or BJ siKrasG12D–1 iExo after 48 hours, compared with untreated cells. Numbers represent the percentage of positive cells (n = 4 independent experiments, 1-way ANOVA compared with untreated). (C) KRASG12D transcript levels in Panc-1 cells treated with MSC Ctrl Exo, MSC siScrbl iExo, MSC siKrasG12D–1 iExo, or BJ G12D–1 iExo after 3 hours, compared with untreated cells (n = 4 independent experiments, 1-tailed unpaired t test). (D) Representative TEM of MSC exosomes, after electroporation, using either research buffer (RB) or clinical buffer (CB). Scale bar: 100 nm. (E) Representative dot plot of flow cytometry analyses and quantification of apoptosis in Panc-1 cells untreated or treated for 48 hours with MSC siKrasG12D–1 iExo electroporated using either RB or CB. Numbers represent the percentage of positive cells (n = 4 independent experiments, 1-way ANOVA compared with untreated). (F) KRASG12D transcript levels in Panc-1 cells (n = 3 independent experiments, 1-tailed unpaired t test). The mean ± SEM is depicted. *P < 0.05, **P < 0.01, ****P < 0.0001. See Supplemental Source Data 1 and 2.

HHS Vulnerability Disclosure